Your browser doesn't support javascript.
loading
Silent New Brain MRI Lesions in Children with MOG-Antibody Associated Disease.
Fadda, Giulia; Banwell, Brenda; Waters, Patrick; Marrie, Ruth A; Yeh, E Ann; O'Mahony, Julia; Arnold, Douglas A; Bar-Or, Amit.
Affiliation
  • Fadda G; Center for Neuroinflammation and Neurotherapeutics, and Multiple Sclerosis Division, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Banwell B; Center for Neuroinflammation and Neurotherapeutics, and Multiple Sclerosis Division, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Waters P; Division of Child Neurology, Department of Neurology, The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Marrie RA; Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Yeh EA; Departments of Internal Medicine and Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
  • O'Mahony J; Department of Pediatrics, University of Toronto, Toronto, ON, Canada.
  • Arnold DA; Institute of Health Policy, Management and Evaluation, the University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada.
  • Bar-Or A; Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
Ann Neurol ; 89(2): 408-413, 2021 02.
Article in En | MEDLINE | ID: mdl-33210746
ABSTRACT
Anti-myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) antibodies are associated clinically with either a monophasic or relapsing disease course. We investigated the frequency and clinical importance of acquired asymptomatic brain magnetic resonance imaging (MRI) lesions in a prospective incident cohort of 74 MOG-IgG positive children with serial MRI scans over a median of 5 years from presentation. Silent new lesions were detected in 14% of MOG-IgG positive participants, most commonly within the first months post-onset, with a positive predictive value for clinically relapsing disease of only 20%. Detection of asymptomatic lesions alone need not prompt initiation of chronic immunotherapy. ANN NEUROL 2021;89408-413.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Brain / Demyelinating Autoimmune Diseases, CNS / Encephalomyelitis, Acute Disseminated / Asymptomatic Diseases / Myelin-Oligodendrocyte Glycoprotein / Multiple Sclerosis Type of study: Prognostic_studies / Risk_factors_studies Limits: Adolescent / Child / Female / Humans / Male Language: En Journal: Ann Neurol Year: 2021 Document type: Article Affiliation country: Panamá

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Brain / Demyelinating Autoimmune Diseases, CNS / Encephalomyelitis, Acute Disseminated / Asymptomatic Diseases / Myelin-Oligodendrocyte Glycoprotein / Multiple Sclerosis Type of study: Prognostic_studies / Risk_factors_studies Limits: Adolescent / Child / Female / Humans / Male Language: En Journal: Ann Neurol Year: 2021 Document type: Article Affiliation country: Panamá